AIMT - Aimmune Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
1.62B
Enterprise Value 3
1.4B
Trailing P/E
N/A
Forward P/E 1
-7.18
PEG Ratio (5 yr expected) 1
-0.18
Price/Sales (ttm)
N/A
Price/Book (mrq)
7.88
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-6.18

Trading Information

Stock Price History

Beta (3Y Monthly) 0.49
52-Week Change 3-0.74%
S&P500 52-Week Change 312.80%
52 Week High 336.12
52 Week Low 316.95
50-Day Moving Average 322.91
200-Day Moving Average 320.86

Share Statistics

Avg Vol (3 month) 3998.12k
Avg Vol (10 day) 3697.18k
Shares Outstanding 562.67M
Float 36.95M
% Held by Insiders 120.27%
% Held by Institutions 183.74%
Shares Short (Sep 30, 2019) 414.43M
Short Ratio (Sep 30, 2019) 410
Short % of Float (Sep 30, 2019) 432.77%
Short % of Shares Outstanding (Sep 30, 2019) 423.02%
Shares Short (prior month Aug 30, 2019) 412.05M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-45.89%
Return on Equity (ttm)-91.65%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -227.01M
Net Income Avi to Common (ttm)-225.84M
Diluted EPS (ttm)-3.73
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)243.67M
Total Cash Per Share (mrq)3.89
Total Debt (mrq)51.58M
Total Debt/Equity (mrq)25.17
Current Ratio (mrq)5.80
Book Value Per Share (mrq)3.27

Cash Flow Statement

Operating Cash Flow (ttm)-184.81M
Levered Free Cash Flow (ttm)-110.92M